An interpretable radiomics model to select patients for radiotherapy after surgery for WHO grade 2 meningiomas

Chae Jung Park1†, Seo Hee Choi2†, Jihwan Eom3, Hwa Kyung Byun4, Sung Soo Ahn1, Jong Hee Chang5, Se Hoon Kim6, Seung-Koo Lee1, Yae Won Park1* and Hong In Yoon4*

Abstract

Objectives: This study investigated whether radiomic features can improve the prediction accuracy for tumor recurrence over clinicopathological features and if these features can be used to identify high-risk patients requiring adjuvant radiotherapy (ART) in WHO grade 2 meningiomas.

Methods: Preoperative magnetic resonance imaging (MRI) of 155 grade 2 meningioma patients with a median follow-up of 63.8 months were included and allocated to training (n = 92) and test sets (n = 63). After radiomic feature extraction (n = 200), least absolute shrinkage and selection operator feature selection with logistic regression classifier was performed to develop two models: (1) a clinicopathological model and (2) a combined clinicopathological and radiomic model. The probability of recurrence using the combined model was analyzed to identify candidates for ART.

Results: The combined clinicopathological and radiomics model exhibited superior performance for the prediction of recurrence compared with the clinicopathological model in the training set (area under the curve [AUC] 0.78 vs. 0.67, \( P = 0.042 \)), which was also validated in the test set (AUC 0.77 vs. 0.61, \( P = 0.192 \)). In patients with a high probability of recurrence by the combined model, the 5-year progression-free survival was significantly improved with ART (92% vs. 57%, \( P = 0.024 \)), and the median time to recurrence was longer (54 vs. 17 months after surgery).

Conclusions: Radiomics significantly contributes added value in predicting recurrence when integrated with the clinicopathological features in patients with grade 2 meningiomas. Furthermore, the combined model can be applied to identify high-risk patients who require ART.

Keywords: Magnetic resonance imaging, Meningioma, Radiomics, Radiotherapy, Prognosis

Introduction

Meningiomas are the most common primary intracranial neoplasms in adults, comprising 36.7% of all intracranial tumors [1]. Since the serial updates of the World Health Organization (WHO) grading classification, the proportion of grade 2 meningiomas has gradually increased up to 15–20% [2]. However, despite recent WHO grading scheme, there are limitations in predicting the prognosis of grade 2 meningiomas [3]. Grade 2 meningiomas are known to have an unpredictable heterogeneous disease course; even after gross total resection (GTR), recurrence...
can occur in a substantial number of patients [4, 5], whereas some patients experience a long indolent clinical course without adjuvant treatment [6].

Currently, adjuvant radiotherapy (ART) is recommended as a standard therapy for patients who undergo subtotal resection (STR) in grade 2 meningiomas [7] based on evidence indicating improvement in local control and survival rates with ART [8–10]. However, there is a lack of consensus on whether ART reduces the risk of tumor recurrence after GTR of grade 2 meningiomas [3]. Thus, it is crucial to establish a model for predicting a patient’s individual outcome and to identify high-risk patients who could benefit from ART even after GTR of grade 2 meningiomas. Patients who are at a low risk for recurrence can be spared from ART and its potential risks. Furthermore, in a set of patients who have undergone STR, patient subsets with a higher risk of recurrence may undergo more intensified radiotherapy to improve their respective outcomes.

Radiomics is an advanced technique that extracts high-dimensional quantitative imaging features, such as intensity distributions, spatial relationships, textural heterogeneity, and shape descriptors [11, 12]. Radiomics aims to discover meaningful “hidden” information within radiological images that is visually inaccessible. Previous studies have demonstrated the use of radiomics in differential diagnosis and grade prediction for meningiomas [13–15]. Some studies have also shown that radiomics can predict tumor recurrence in patients with meningiomas [16, 17]. We hypothesized that radiomics can enable risk stratification for tumor recurrence after surgery in patients with grade 2 meningiomas, which may guide patients toward ART.

Therefore, this study aimed to investigate whether radiomics features can be used to improve the prediction of tumor recurrence over clinicopathological features, and if radiomics can be used to identify high-risk patients who require ART in WHO grade 2 meningiomas.

Methods

Patient population

This study was approved by the institutional review board of the Yonsei University Health System (9-2021-0047). The institutional review board waived the requirement to obtain informed patient consent for this retrospective study. We retrospectively reviewed 199 patients with surgically confirmed WHO grade 2 meningiomas who underwent preoperative conventional magnetic resonance imaging (MRI) between February 2005 and November 2018. The exclusion criteria were as follows: (1) incomplete MRI sequences (n = 30), (2) suboptimal image quality (n = 6), (3) patients who received stereotactic radiotherapy (n = 5), and (4) lack of Ki-67 labeling index (n = 3). Finally, a total of 155 patients were enrolled (Additional file 1: Fig. S1). The study population was randomly divided into training and test sets with a ratio of 6:4 (n = 92 and n = 63, respectively).

Preoperative MRI was performed using a 3.0-T MRI scanner (Achieva, Philips Medical Systems, Amsterdam, Netherlands) with an eight-channel sensitivity-encoding head coil. Detailed parameters of the MRI sequences are provided in Additional file 1: Supplementary Material S1.

Treatments

All patients underwent either GTR (n = 132) or STR (n = 23) surgery. The extent of resection was defined by comparing preoperative and postoperative MRI scans; GTR was defined by a lack of residual enhancing tumor in the image, and STR was defined by the patient having more than 50% of the tumor removed [18]. After surgical resection, a multidisciplinary team, consisting of neurosurgeons, radiation oncologists, neuropathologists, and neuroradiologists, decided whether to perform ART, which consisted of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy. A total of 97 patients underwent ART; 80 patients received it after GTR (80/132, 60.6%), whereas 17 received it after STR (17/23, 73.9%). Among the patients who underwent ART, intensity-modulated radiotherapy was performed on 86 patients (88.7%, median 60.0 Gy), and three-dimensional conformal radiotherapy was performed on 11 patients (11.3%, median 59.4 Gy).

Response assessment by a neuro-oncology meningioma working group

The evaluation of the tumor response and progression was determined according to the Response Assessment in Neuro-Oncology (RANO) criteria [19] by comparing serial MRIs of each patient. A radiation oncologist and neuroradiologist (with 9 and 8 years of experience, respectively) performed the evaluation and the results were achieved by consensus. A detailed description of the RANO criteria and the definitions of each assessment criteria are presented in the Additional file 1: Supplementary material S2 and Additional file 1: Table S1. The patients assessed as having a progressive disease in the follow-up periods were considered to have tumor recurrence. Patients assessed as having complete response, partial response, minor response, and stable disease were considered to be patients without tumor recurrence. The primary endpoint was tumor recurrence assessed by the RANO criteria during the follow-up period.

Image preprocessing and radiomic feature extraction

Preprocessing of the T2 and T1C images was performed to standardize the data analysis across patients.
Before analysis, the N4 bias correction algorithm was applied [20], and images were z-score normalized. Images were processed using an open-source software package (3D Slicer, version 4.11.0; available at: http://slicer.org/). T1C images were coregistered to T2 images via affine transformation with normalized mutual information as a cost function [21, 22]. The regions of interest were drawn on every tumor section on the T1C images using threshold-based and edge-based algorithms. Gross cystic, hemorrhagic, or necrotic areas of the tumors were included in the regions of interest (ROIs). The segmentations were transferred to the T2 images. A neuroradiologist (8 years of experience) performed segmentation which was confirmed by a second neuroradiologist (11 years of experience). Both neuroradiologists were blind to the corresponding clinical information.

Discretization using a fixed bin number of 32 was applied to extract the radiomic features [23] from the ROIs using an open-source Python-based module (PyRadiomics, version 2.0) [24], which adhered to the Image Biomarker Standardization Initiative [25]. Fourteen shape features, 18 first-order features, and 75 second-order features (24 Gy-level co-occurrence matrices, 16 Gy-level run length matrices, 16 Gy-level dependence matrices, and 5 neighborhood gray-tone difference matrices) were extracted from the ROIs in the T1C and T2 images (Additional file 1: Table S2), comprising a total of 200 radiomic features. A schematic of the data processing is shown in Fig. 1.

**Model construction and comparison of diagnostic performance**

The number of radiomic features was larger than the number of cases; therefore, the least absolute shrinkage and selection operator (LASSO) was applied to select the significant features, which optimized the feature space by removing both irrelevant and redundant features [18]. The base radiomics classifiers were constructed using logistic regression with tenfold cross validation. In addition, each model was trained using random oversampling examples (ROSE) to overcome any data imbalance, and hyperparameters were Bayesian optimized. To evaluate whether radiomics improves the prediction of models, two models were trained as follows: (1) a clinicopathological model trained on clinical features, including age, extent of resection, ART status, and Ki-67 index; and (2) a combined model trained on clinicopathological and radiomics features. For statistical analysis, the Ki-67 index was dichotomized based on a cutoff value of 5% (≤ 5% vs. > 5%). Models were developed from the training set (n = 92) and validated on the test set (n = 63). The area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, and specificity were obtained. The feature selection and machine learning process were performed using Python 3 (Python Software Foundation,
Wilmington, Delaware, USA) with the Scikit-Learn library module (version 0.21.2). The performances of the models were compared based on the AUC using DeLong’s method [26].

**Model interpretability with SHapley Additive exPlanations**

To interpret and analyze the radiomic features of the radiomics model, SHapley Additive exPlanations (SHAP), which is a game theoretic approach to explain the output of a tree-based machine learning model (Additional file 1: Supplementary Material S3), was applied [27]. SHAP measures the contribution of each feature of a model against the increase or decrease of the probability of a single output (i.e., the probability for tumor recurrence in our study) (Fig. 2).

**Analysis of survival outcomes and stratification for candidates for ART**

After constructing the best combined model for predicting tumor recurrence, the probability value of each patient in the test set was analyzed to stratify candidates for ART. Youden’s index was used for the optimal cut-off selection threshold, and a cut-off probability value of 0.3 was obtained in the training set. The identical threshold value was applied to the test set, and patients were divided into low- and high-risk groups. We retrospectively analyzed whether patients in low- and high-risk groups benefited from ART by comparing the progression-free survival (PFS). PFS was defined as the time from initial surgery to tumor recurrence, death, or the last follow-up. Kaplan–Meier curves were generated and a log-rank test was performed to test the difference of PFS between patients who did and did not receive ART for each risk subgroup.

**Statistical analysis**

The Student’s t-test, Mann–Whitney U-test, and Chi-square test were performed to compare patient characteristics between the responders and nonresponders from training and test sets. The Kaplan–Meier method was used to estimate survival rates, and the log-rank test was performed to compare survival between the two groups. A P-value < 0.05 was considered statistically significant. All statistical analyses were performed using statistical software R (version 4.0.1; R Foundation for Statistical Computing, Vienna, Austria) and SPSS (version 25.0; SPSS Inc., Chicago, IL).
Results

Patient characteristics

Among 155 patients (mean age 56.9 ± 14.3, 102 females and 53 males), 148 had atypical meningiomas, 6 had choroid meningioma, and 1 had clear cell meningioma. In the training set, GTR was more frequently performed in patients without tumor recurrence compared to those with tumor recurrence (87.5% vs. 58.3%, P = 0.011). No other clinicopathological features were different between patients with and without tumor recurrence. In the test set, GTR was more frequently performed in patients without tumor recurrence compared to those with tumor recurrence (90.7% vs. 66.7%, P = 0.045). Patients with tumor recurrence were significantly older (P = 0.020), showed a male predominance (P = 0.031), and had a higher Ki-67 labeling index (≥ 5%) (P = 0.018). ART was performed in 56 (60.9%) and 41 patients (65.1%) in the training and test sets, respectively. There were no significant differences between the training and test sets with respect to the clinical and pathologic variables. The clinicopathological characteristics of the training and test sets are summarized in Table 1.

Treatment outcomes and prognostic factors

With a median follow-up of 63.8 months (range, 6.6–190.7 months), there were 21 patients with tumor recurrence (12 [13.0%] in the training set, and 9 [14.3%] in the test set). Fifteen events occurred within 24 months (7 in the training set, and 8 in the test set, P = 0.292). The 5-year PFS rate was 79.1% for the entire cohort, and 79.9% and 78.9% for the training and test set, respectively (P = 0.529).

In the training set, tumor recurrences occurred more frequently in patients who underwent STR than in those who underwent GTR (33.3% vs. 9.1%, P = 0.011). The recurrence rate was higher in patients with a Ki-67 index value of 5% or more, although it was not statistically significant (19.1% vs. 6.7%, P = 0.076). In the test set, the recurrence rate was higher in patients who underwent STR (37.5% vs. 10.9%, P = 0.045) and in patients with Ki-67 ≥ 5% (24.2% vs. 3.3%, P = 0.018).

Radiomics model construction of recurrences and comparison of diagnostic performance

In the clinicopathological model, the AUC, accuracy, sensitivity, and specificity were 0.67 (95% confidence interval [CI] 0.60–0.74), 66.9%, 48.2%, and 85.3% in the training

| Table 1 Patient characteristics in the training and test sets |
|---------------------------------------------------------------|
| **Clinical variables** | **Training set (n = 92)** | **P-value** | **Test set (n = 63)** | **P-value** | **P-value** |
| | **Without tumor recurrence** | **With tumor recurrence** | | **Without tumor recurrence** | **With tumor recurrence** | |
| | (n = 80) | (n = 12) | | (n = 54) | (n = 9) | |
| Age (years) | 57.3 ± 14.6 | 54.4 ± 13.6 | 0.530 | 55.7 ± 14.1 | 67.7 ± 13.2 | 0.020 | 0.838 |
| Female ratio | 52 (65.0%) | 9 (75.0%) | 0.494 | 38 (70.4%) | 3 (33.3%) | 0.031 | 0.875 |
| Extent of resection | 0.011 | | | | | |
| GTR | 70 (87.5%) | 7 (58.3%) | | 49 (90.7%) | 6 (66.7%) | 0.114 | 0.535 |
| STR | 10 (12.5%) | 5 (41.7%) | | 5 (9.3%) | 3 (33.3%) | | |
| Ki-67 labeling index | 6.03 ± 4.81 | 6.96 ± 2.73 | 0.515 | 5.9 ± 4.3 | 8.2 ± 3.1 | 0.131 | 0.875 |
| < 5% | 32 (40.0%) | 3 (25.0%) | 0.076 | 29 (53.7%) | 1 (11.1%) | 0.018 | 0.081 |
| ≥ 5% | 38 (47.5%) | 9 (75.0%) | | 25 (46.3%) | 8 (88.9%) | | |
| ART | | | | 0.659 | | | |
| Performed | 48 (60.0%) | 8 (66.7%) | | 36 (66.7%) | 5 (55.6%) | 0.517 | 0.631 |
| Not performed | 32 (40.0%) | 4 (33.3%) | | 18 (33.3%) | 4 (44.4%) | | |
| ART modalityc | | | | 0.851 | | | |
| 3D-CRT | 5 (10.4%) | 2 (25.0%) | | 2 (5.6%) | 2 (40.0%) | 0.061 | 0.631 |
| IMRT | 43 (89.6%) | 6 (75.0%) | | 34 (94.4%) | 3 (60.0%) | | |
| ART dose (Gy)c | 57.3 ± 4.0 | 57.2 ± 6.7 | 0.956 | 58.3 ± 3.9 | 58.7 ± 2.6 | 0.853 | 0.204 |

Data are expressed as the mean with standard deviation in parentheses, median with interquartile range in parentheses, or number with percentage in parentheses

a Calculated from Student’s-t test for continuous variables and Chi-square test for categorical variables to compare the patient characteristics between the responder and non-responders from each training and test set

b Calculated from Student’s-t test for continuous variables and Chi-square test for categorical variables for the comparison of training and test sets

c Data obtained from patients who underwent adjuvant radiotherapy following surgery

GTR: gross total resection; STR: subtotal resection; ART: adjuvant radiotherapy; RT: radiotherapy; 3D-CRT: three-dimensional conformal radiotherapy; IMRT: intensity modulated radiotherapy
In the combined clinicopathological and radiomics model, a total of seven features were selected: two clinical features (extent of resection [GTR or STR] and Ki-67 index [≥5% or <5%]) and five radiomic features, which were all first-order features from T1C (10th percentile, 90th percentile, entropy, mean absolute deviation, and minimum) (Additional file 1: Table S3). The AUC, accuracy, sensitivity, and specificity were 0.78 (95% CI 0.70–0.85), 75.0%, 76.8%, and 73.1% in the training set, and 0.77 (95% CI 0.60–0.94), 70.3%, 66.7%, and 70.9%, respectively, in the test set.

In the training set, the combined model achieved superior performance compared with the clinicopathological model (AUC: 0.78 vs. 0.67, \(P = 0.042\)) (Fig. 3, Table 2). In the test set, the combined model trended toward better performance in the test set than in the clinicopathological model (AUC: 0.77 vs. 0.61, \(P = 0.192\)) without statistical significance. The diagnostic performances of the two models in the training and test set are provided in Table 2.

**Model interpretability with SHAP**

The SHAP values for each selected feature in the combined clinicopathological and radiomics model were calculated. The variance importance plot, summary plot, decision plot, and force plot of the test set are shown in Fig. 4. For each prediction, a positive SHAP value indicates an increase in the risk of tumor recurrence while a negative SHAP value indicates reduced risk. As observed in the plots, the extent of resection, 90th percentile from T1C, and Ki-67 index are the three most important risk factors.

**Selection of candidates for ART using the developed combined model**

In the test set, there were 49 patients in the high-risk group and 14 patients in the low-risk group according to the combined clinicopathological and radiomics model. The characteristics of patients in the high- and low-risk groups are summarized in Additional file 1: Table S4. Among all patients, those who received ART exhibited a significantly longer PFS (5-year PFS, 87.8% vs. 65.4%, \(P = 0.035\)) and delayed recurrence (median time to recurrence 45.3 vs. 18.4 months) (Fig. 2a, c). In the high-risk group, the PFS was significantly longer in patients who received ART (5-year PFS, 92.3% vs. 56.8%, \(P = 0.024\)) (Fig. 2b), with significantly delayed recurrence (median 53.5 vs. 17.0 months). In the low-risk group, there was no significant difference in the PFS (\(P = 0.264\)) or recurrence interval with respect to ART. Only one patient experienced tumor recurrence (39.9 months after surgery).

When the cohort of patients was divided into four groups according to ART status and recurrence probability, the PFS was observed to significantly improve after ART in patients with a high recurrence probability (median 8.7 year, 5-year 92.3%) (Fig. 2d). The significant improvement in PFS was observed regardless of the extent of resection (GTR: 5-year 91.3% vs. 63.5%, \(P = 0.054\); STR: 5-year 100.0% vs. 0.0%, \(P = 0.012\)).

---

![Fig. 3](image-url)  
**Fig. 3** Receiver operating characteristic curves of the radiomics model in the a training and b test sets
Table 2 Performances of machine learning models for prediction of tumor recurrence in the training and test set

| Models                        | Training set                  | Test set                     |
|-------------------------------|-------------------------------|------------------------------|
|                               | AUC (95% CI)                  | Accuracy (%)                | Sensitivity (%) | Specificity (%) | P value |
| Clinicopathological model     | 0.67 (0.59–0.74)              | 66.9                         | 48.2            | 85.3            | Reference |
| Clinicopathological + radiomics model | 0.78 (0.70–0.85)              | 75.0                         | 76.8            | 31.0            | 0.042     |

AUC: area under the curve; CI: confidence interval; NRI: net reclassification index
Discussion

In this study, radiomic features derived from preoperative MRI were applied to predict tumor recurrence in grade 2 meningiomas. The model incorporating radiomic features with clinicopathologic features exhibited significantly a higher prediction accuracy for tumor recurrence. Several risk factors for tumor recurrence were identified using SHAP, and the contribution of each feature to the probability of tumor recurrence was determined. Further, radiomics enabled a subset of patients at a high risk for tumor recurrence to be identified, and we observed that the high-risk patients clearly benefitted from ART. Therefore, radiomics can serve as a potential imaging biomarker, as well as a useful tool for selecting adequate candidates for ART in patients with meningiomas.

Although the majority of meningiomas are benign and slow growing, WHO grade 2 meningiomas are considered to have a high recurrence rate of 55% and low survival rates [28–30]. ART after the STR of grade 2 meningiomas is widely practiced; however, the impact of ART on grade 2 meningiomas after a GTR remains contentious. Several researchers demonstrated improved local control and/or survival [8–10, 30–33] with ART after GTR, but a subset exhibited contrary results after ART [9, 34–36]. According to two multinstitutional phase II studies (NRG Oncology RTOG 0539 [32] and EORTC 22,042–26,042 [37]), which enrolled grade 2 meningioma patients who underwent GTR and ART, there is a potential survival benefit with a 3-year PFS of 89%–94%. However, those studies did not directly compare ART with upfront observation, and risk factors other than surgical resection were not addressed. Therefore, a uniform treatment paradigm for resected grade 2 meningiomas has yet to be established.

Because there is a lack of standardized treatment for resected grade 2 meningiomas, performing noninvasive risk stratification prior to adjuvant therapies is highly desirable. Even after surgical resection, patients at high-risk for tumor recurrence can be considered for intensified adjuvant therapies, and patients at low-risk for tumor recurrence can be spared from experiencing the possible neurotoxicities of ART [38]. Several previous studies investigated clinical prognostic factors for grade 2 meningiomas, which included age, sex, extent of resection, tumor invasiveness (i.e., brain or bone invasion), and higher MIB-1 labeling index [39, 40]. Similar to our study, the clinical significance of the Ki-67 labeling index on local control and survival in high-grade meningiomas has been widely reported. A higher Ki-67 labeling index seems to be related to invasiveness, which is closely correlated with an incomplete resection rate. Although there is some discrepancy in the exact cutoff point, several studies have suggested the need for ART in patients with a higher Ki-67 [41, 42]. Pretreatment tumor size or volume was also reported as a significant predictor of prognosis [35, 43–45]. However, in our study that analyzed various radiomic features including tumor size, it was not a significant prognostic factor compared to other features.

Several studies attempted to identify the prognostic value of radiomics in patients with meningiomas [16, 17, 46]. However, these previous studies combined grade 1–3 meningiomas and do not provide specific information on the utility of the radiomics model for grade 2 meningiomas. Moreover, neither the combined clinicopathological model nor radiomics model showed any improved performance in predicting prognosis compared with the clinicopathological model alone, limiting the real-world application of the radiomics model [17, 46]. Decision-making for the treatment of grade 2 meningioma patients depends on multilevel prognostic information and clinicopathological information, such as the extent of the tumor resection or Ki-67 index; therefore, we focused on the role of radiomics in predicting survival given the multilevel prognostic information. Our results show that radiomics significantly increases the model performance when added to a clinicopathological model, thus promoting the integration of radiomics in clinical practice.

Radiomics models have limited explainability because they rely on complex machine learning algorithms, resulting in low clinical utility [47]. SHAP can
Fig. 4 (See legend on previous page.)
uncover complex underlying patterns [27, 48] and has recently been utilized to interpret radiomics models [49, 50]. This analysis identified two clinical features—the extent of resection and the Ki-67 labeling index—and five radiomic first-order features from T1C that contributed the most towards the prediction of tumor recurrence. The extent of resection and the Ki-67 index are well-known prognostic factors for tumor recurrence [35, 51], which was also verified by our study. The 90th and 10th percentile values from T1C, which are the two most important radiomic features, denote the intensity of contrast enhancement. Heterogeneous contrast enhancement or the presence of contrast enhancement of meningiomas [17] has shown significant association with high-grade meningiomas or tumor invasiveness [52, 53]; therefore, the meningioma grade may be indicated by the percentile-related first-order features, which reflect the distribution of the contrast-enhancement degree.

Our study has several limitations. First, our study was based on a single-center, retrospectively collected dataset. Further studies with a larger number of patients and external validations are required. Second, the histopathologic risk factors, such as the MIB-1 labeling index or mitoses index, were not evaluated in our study because relevant information for the majority of patients were unavailable during the long study-inclusion period. To prove the predictive values of radiomics, it is highly desirable to incorporate detailed histopathologic features into the models in future studies. Third, the probability scores derived from the developed model for tumor recurrence were only calculated in the test set, not in the training set, because the training set was oversampled during the development of the model. Therefore, the benefit of ART was only evaluated in the test set, which inevitably decreased the sample size. However, based on our study results, we at least found a benefit of ART in a subgroup of the test set, which was identified through the combined model. Future studies with larger sample sizes are required to identify the patients with grade 2 meningiomas who might benefit from ART.

Our study is the first to show the possibility of radiomics playing an important role in selecting candidate patients with meningiomas for ART. Over a similar follow-up period (median 54 months in ART group vs. 61 months in non-ART group, P = 0.584), we observed that ART prolongs PFS and significantly delays recurrence in high-risk patients. Our combined predictive model could be applied effectively and conveniently in both GTR and STR patients.

Conclusions

Multiparametric MRI radiomics has an added prognostic value for the prediction of tumor recurrence when integrated with clinicopathologic profiles in patients with grade 2 meningiomas. With radiomics, we could identify a subset of patients at a high risk for tumor recurrence who might benefit from intensified treatment. Therefore, radiomics may be used as a potential imaging biomarker in patients with grade 2 meningiomas.

Abbreviations
ART: Adjuvant radiotherapy; GTR: Gross total resection; LASSO: Least absolute shrinkage and selection operator; PFS: Progression-free survival; RANO: Response assessment in neuro-oncology; ROI: Region of interest; ROSE: Random over-sampling examples; SHAP: Shapley Additive Explanations; STR: Subtotal resection; T1C: Post-contrast T1-weighted image; T2: T2-weighted image; WHO: World Health Organization.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13014-022-02090-7.

Acknowledgements
None

Author contributions
SHC and CJP analyzed, interpreted the patient data and wrote the manuscript. SHC, CJP, JE, and HKB are contributors for analysis. YWP and HIY are major contributors for conceptualization and interpretation. All authors read and approved the final manuscript.

Funding
This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (Republic of Korea; grant number: NRF-2020R1I1A1A0107164811 to Y. W. Park) and the National Research Foundation of Korea (NRF) Grant funded by the Korea government (MSIT) (NRF-2021R1A2C1010908 to S. H. Choi). This study was also supported by a faculty research grant of Yonsei University College of Medicine for (6-2020-0115).

Availability of data and materials
Research data are stored in an institutional repository and will be shared upon request to the corresponding author.

Declarations

Ethics approval and consent to participate
This study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the institutional review board of the Yonsei University Health System (9-2021-0047).

Consent for publication
Not applicable.

Competing interests
None of the authors have any conflicts of interest to disclose.

Author details
1Department of Radiology, Research Institute of Radiological Science and Center for Clinical Imaging Data Science, Yonin Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea. 2Department of Radiation Oncology, Yonin Severance Hospital, Yonsei University College.
of Medicine, Seoul, Republic of Korea. 2Department of Computer Science, Yonsei University, Seoul, Republic of Korea. 3Department of Radiation Oncology, Yonsei Cancer Center, Heavy Ion Therapy Research Institute, Yonsei University College of Medicine, Seoul, Republic of Korea. 4Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Republic of Korea.

Received: 14 March 2022 Accepted: 23 June 2022

Published online: 22 August 2022

References

1. Ostrom QT, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011. Neuro Oncol. 2014;16(Suppl 4):i1–63.

2. Ostrom QT, Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011–2015. Neuro Oncol. 2018;20(4):iv–i–86.

3. Goldbrunner R, Stavrou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021;23(11):1390–4.

4. Stark AM, Buhl R, Mehdorn HM. Early gross recurrence of atypical meningioma. J Neurooncol. 2005;75(2):223–4.

5. Jenkinson MD, Waqar M, Farah JO, Farrell M, Barbagallo GM, McManus R, et al. Early adjuvant radiotherapy in the treatment of atypical meningioma. J Clin Neurosci. 2016;28:87–92.

6. Lee KD, Defowell J, Ar EI, Dwivedi AK, Kendler A, McPherson CM. Atypical meningiomas: postoperative radiotherapy indicated? Neurosurg Focus. 2013;35(6):E15.

7. Goldbrunner R, Stavrou P, Jenkinson MD, Sahm F, Mawrin C, Weber DC, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021. https://doi.org/10.1093/neucom/noab150.

8. Park HJ, Kang HC, Kim IH, Park SH, Kim DG, Park CK, et al. The role of adjuvant radiotherapy in atypical meningioma. J Neurooncol. 2013;115(2):241–7.

9. Bagshaw HP, Burt LM, Jensen RL, Suneja G, Palmer CA, Coulwdell WT, et al. Adjuvant radiotherapy for atypical meningiomas. J Neurosurg. 2017;126(6):1822–9.

10. Choi Y, Lim DH, Jo K, Nam DH, Seoel HJ, Lee JI. Efficacy of postoperative radiotherapy for high grade meningiomas. J Neurooncol. 2014;119(2):405–12.

11. Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology. 2016;278(2):563–77.

12. Park YW, Han K, Ahn SS, Choi YS, Chang JH, Kim SH, et al. Whole-tumor radiomics and 1p/19q-codeletion status in world health organization grade II gliomas. AJNR Am J Neuroradiol. 2018;39(4):693–8.

13. Won SY, Park YW, Ahn SS, Moon JH, Kim EH, Kang SG, et al. Quality of Pathology, Yonsei University College of Medicine, Seoul, Republic of Korea.

14. deGroot NM, Haste T, Tibshirani R. Regularization paths for generalized linear models via coordinate descent. J Stat Softw. 2010;33(1):1–22.

15. Huang RY, Bi WL, Weller M, Kaley T, Blakeley J, Dunn I, et al. Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. Neuro Oncol. 2019;21(1):26–36.

16. Tustison NJ, Avants BB, Cook PA, Zheng Y, Egan A, Yushkevich PA, et al. N4ITK: improved N3 bias correction. IEEE Trans Med Imaging. 2010;29(6):1310–20.

17. Cha J, Kim ST, Kim HJ, Kim BJ, Kim YK, Lee JY, et al. Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis. AJNR Am J Neuroradiol. 2014;35(7):1309–17.

18. Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P. Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging. 1997;16(2):187–98.

19. Carré A, Klausner G, Edjlali M, Lerousseau M, Briend-Diop J, Sun R, et al. Standardization of brain MR images across machines and protocols: bridging the gap for MRI-based radiomics. Sci Rep. 2020;10(1):12340.

20. van Grijthuijsen JM, Federov A, Parmar C, Hosny A, Auc Moreno V, et al. Computational radiomics system to decode the radiographic phenotype. Cancer Res. 2017;77(21):e104–7.

21. Zwanenburg A, Leger S, Vallier S, Moll L. Image biomarker standardisation initiative. arXiv preprint arXiv:1612.07003. 2016.

22. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837–45.

23. Lundberg SM, Lee S-I. A unified approach to interpreting model predictions. In: Proceedings of the 31st international conference on neural information processing systems; 2017. pp. 4768–77.

24. Modha A, Gutin PH. Diagnosis and treatment of atypical and anaplastic meningiomas: a review. Neurosurgery. 2005;57(2):538–50.

25. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raiser J, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015;122(1):4–23.

26. Aizer AA, Bi WL, Kandola MS, Lee EQ, Nayak L, Rinne ML, et al. Extent of resection and overall survival for patients with atypical and malignant meningioma. Cancer. 2015;121(4):4376–81.

27. Li H, Zhang YS, Zhang GB, Zhang GJ, Wang B, Li D, et al. Treatment protocol, long-term follow-up, and predictors of mortality in 302 cases of atypical meningioma. World Neurosurg. 2019;122:e1275–84.

28. Rogers L, Zhang P, Vogelbaum MA, Perry A, Ashby LS, Modi JM, et al. Intermediate-risk meningioma: initial outcomes from NRG Oncology RTOG 0539. J Neurosurg. 2018;129(1):35–47.

29. Rydzewski NR, Lesniak MS, Chandler JP, Kalapurakal JA, Pollem E, Tate MC, et al. Gross total resection and adjuvant radiotherapy most significant predictors of improved survival in patients with atypical meningioma. Cancer. 2018;124(4):4374–42.

30. Zhu H, Bi WL, Aizer P, Ahn L, Tian M, Den J, et al. Efficacy of adjuvant radiotherapy for atypical and anaplastic meningioma. Cancer Med. 2019;8(1):13–20.

31. Zhi M, Girvégian NR, Miller MJ, Chen JC, Schumacher AJ, Rahimian, J, et al. Long-term outcomes of newly diagnosed resected atypical meningiomas and the role of adjuvant radiotherapy. World Neurosurg. 2019;122:e1153–61.

32. Graffeo CS, Leeper HE, Perry A, Uhm JH, Lachance DJ, Brown PD, et al. Revisiting adjuvant radiotherapy after gross total resection of world health organization grade II meningioma. World Neurosurg. 2017;103:655–63.

33. Weber DC, Ares C, Villa S, Peerdeman SM, Renard L, Baumert BG, et al. Adjuvant postoperative high-dose radiotherapy for atypical and malignant meningioma: A phase-ii parallel non-randomized and observational study (EORTC 22042–62042). Radiother Oncol. 2018;128(2):260–5.

34. Wu A, Jin MC, Meola A, Wong H-n, Chang SD. Efficacy and toxicity of particle radiotherapy in WHO grade II and grade III meningiomas: a systematic review. Neurosurgical Focus. 2019;46(6):E12.

35. Wang F, Xu D, Liu Y, Lin Y, Wei Q, Gao Q, et al. Risk factors associated with postoperative recurrence in atypical intracranial meningioma: analysis of 263 cases at a single neurosurgical centre. Acta Neurochir. 2019;161(12):2563–70.

36. Ros-Sanjuan A, Iglesias-Moroxo S, Carrasco-Brenes A, Bautista-Ojeda D, Arreaza-Sanchez MA. Atypical meningiomas: histologic and clinical factors associated with recurrence. World Neurosurg. 2019;125:e248–56.
41. Choi Y, Lim DH, Yu JI, Jo K, Nam DH, Seol HJ, et al. Prognostic value of Ki-67 labeling index and postoperative radiotherapy in WHO grade II meningioma. Am J Clin Oncol. 2018;41(1):18–23.

42. Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A. Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology. 2007;27(2):114–20.

43. Detti B, Scoccianti S, Di Cataldo V, Monteleone E, Cipressi S, Bordi L, et al. Atypical and malignant meningioma: outcome and prognostic factors in 68 irradiated patients. J Neurooncol. 2013;115(3):421–7.

44. Milker-Zabel S, Zabel A, Schulz-Ertner D, Schlegel W, Wannenmacher M, Debus J. Fractionated stereotactic radiotherapy in patients with benign or atypical intracranial meningioma: long-term experience and prognostic factors. Int J Radiat Oncol Biol Phys. 2005;61(3):809–16.

45. Zhang GJ, Zhang YS, Zhang GB, Yan XJ, Li CB, Zhang LW, et al. Prognostic factors, survival, and treatment for intracranial world health organization grade ii chordoid meningiomas and clear-cell meningiomas. World Neurosurg. 2018;117:e57–66.

46. Gennatas ED, Wu A, Braunstein SE, Morin O, Chen WC, Magill ST, et al. Preoperative and postoperative prediction of long-term meningioma outcomes. PLoS ONE. 2018;13(9): e0204161.

47. Du R, Lee VH, Yuan H, Lam K-Q, Pang HH, Chen Y, et al. Radiomics model to predict early progression of nonmetastatic nasopharyngeal carcinoma after intensity modulation radiation therapy: a multicenter study. Radiol Artif Intell. 2019;1(4):e180075.

48. Arrow K, Barankin E, Blackwell D. Admissible points of convex sets. Contrib Theory Games. 1953;2:87–91.

49. Bang M, Eom J, An C, Kim S, Park YW, Ahn SS, et al. An interpretable multiparametric radiomics model for the diagnosis of schizophrenia using magnetic resonance imaging of the corpus callosum. Transl Psychiatry. 2021;11(1):462.

50. Giraud P, Giraud P, Nicolas E, Boisselier P, Alfonsi M, Rives M, et al. Interpretable machine learning model for locoregional relapse prediction in oropharyngeal cancers. Cancers. 2021;13(1):57.

51. Mirian C, Skyrmann S, Bartek J Jr, Jensen LR, Kihlström L, Förander P, et al. The Ki-67 proliferation index as a marker of time to recurrence in intracranial meningioma. Neurosurgery. 2020;87(6):1289–98.

52. Adeli A, Hess K, Mawrin C, Streckert EMS, Stummer W, Paulus W, et al. Prediction of brain invasion in patients with meningiomas using preoperative magnetic resonance imaging. Oncotarget. 2018;9(89):35974–82.

53. Liu Y, Chotal S, Chen M, Jin S, Qi S-t, Pan J. Preoperative radiologic classification of convexity meningioma to predict the survival and aggressive meningioma behavior. PLoS ONE. 2015;10(3):e018908-e.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.